GlassScriptPhysician profile
Brian Kent Ulrich
NPI 1811975063
$4,994.92
in general payments reported to CMS, 2019-2025
60 companies · $679 in 2025
The $679 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $632 · 2020: $221 · 2021: $902 · 2022: $873 · 2023: $1,211 · 2024: $479 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.80 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $300.86 | 2022-2024 | Jardiance, Gilotrif |
| Astrazeneca Pharmaceuticals LP | $286.64 | 2022-2024 | Imfinzi, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $271.65 | 2019-2025 | Iclusig |
| Janssen Biotech, INC. | $265.13 | 2021-2025 | Erleada, Akeega, Balversa |
| Glaxosmithkline, LLC. | $237.52 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Adaptive Biotechnologies Corporation | $208.78 | 2020-2023 | Clonoseq |
| Lilly USA, LLC | $187.94 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $182.25 | 2022-2024 | Pemazyre, Jakafi |
| Pfizer INC. | $176.61 | 2019-2023 | |
| Blueprint Medicines Corporation | $166.67 | 2021-2024 | Ayvakit |
| Kite Pharma, INC. | $148.96 | 2021-2022 | |
| Exelixis INC. | $148.65 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $142.94 | 2023-2025 | Keytruda, Welireg |
| E.R. Squibb & Sons, L.L.C. | $137.04 | 2023-2025 | Pomalyst, Opdivo |
| Pharmacyclics LLC, An Abbvie Company | $129.57 | 2019-2023 | Imbruvica, Epkinly |
Show all 56 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ulrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.